Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Atte Kivisaari is active.

Publication


Featured researches published by Atte Kivisaari.


British Journal of Dermatology | 2010

Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma

Atte Kivisaari; Markku Kallajoki; Risto Ala-aho; John A. McGrath; Johann W. Bauer; R. Königová; Márta Medvecz; W. Beckert; Reidar Grénman; Veli-Matti Kähäri

Background  Tumour‐specific expression of matrix metalloproteinase (MMP)‐7 has been noted in cutaneous squamous cell carcinomas (SCCs) in patients with recessive dystrophic epidermolysis bullosa (RDEB).


British Journal of Dermatology | 2008

Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas

Atte Kivisaari; Markku Kallajoki; T Mirtti; John A. McGrath; Johann W. Bauer; F. Weber; R. Königová; Daisuke Sawamura; Kazuko C. Sato-Matsumura; Hiroshi Shimizu; Márta Csikós; K Sinemus; W. Beckert; Veli-Matti Kähäri

Background  Patients with recessive dystrophic epidermolysis bullosa (RDEB) have an increased risk of developing rapidly progressive and metastatic cutaneous squamous cell carcinomas (SCC). It is unclear why these SCC behave more aggressively than sporadic SCC. Matrix metalloproteinases (MMP) are a family of endopeptidases that contribute to growth, invasion and metastasis of SCC. The role of MMP in RDEB‐associated SCC is not known.


American Journal of Pathology | 2011

Serpin Peptidase Inhibitor Clade A Member 1 (SerpinA1) Is a Novel Biomarker for Progression of Cutaneous Squamous Cell Carcinoma

Mehdi Farshchian; Atte Kivisaari; Risto Ala-aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri

The incidence of keratinocyte-derived nonmelanoma skin cancers is increasing worldwide because of cumulative recreational exposure to sunlight. At present, no specific molecular markers are available for assessing the progression of premalignant actinic keratoses to invasive cutaneous squamous cell carcinoma (SCC). We examined the role of the Serpin family in skin SCCs. Expression profiling of cutaneous SCC cell lines (n = 8) revealed up-regulation of SerpinA1 compared with normal epidermal keratinocytes (n = 5). Analysis with quantitative RT-PCR showed that the mean level of SerpinA1 mRNA was markedly up-regulated in cutaneous SCC cell lines (n = 8) compared with in normal keratinocytes. SerpinA1 production by SCC cells was dependent on p38 mitogen-activated protein kinase activity and was up-regulated by epidermal growth factor, tumor necrosis factor-α, interferon-γ, and IL-1β. Immunostaining of tissue arrays with 148 human tissue samples revealed tumor cell-associated expression of SerpinA1 in 19 of 36 actinic keratoses, 22 of 29 Bowens disease samples, 67 of 71 sporadic SCCs, and all 12 recessive dystrophic epidermolysis bullosa-associated SCCs examined. Moreover, tumor cell-associated SerpinA1 staining was detected in all chemically induced mouse skin SCCs studied (n = 17). Overexpression of SerpinA1 mRNA was also detected by quantitative RT-PCR in chemically induced mouse skin SCCs (n = 14) compared with control tissues (n = 14). These data identify SerpinA1 as a novel tumor cell-associated biomarker for progression of cutaneous SCCs.


Acta Oto-laryngologica | 2008

Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer

Heikki Luukkaa; Pekka J. Klemi; Pirkko Hirsimäki; Tero Vahlberg; Atte Kivisaari; Veli-Matti Kähäri; Reidar Grénman

Conclusions. In the current study matrix metalloproteinases (MMPs)-9 and -13 were associated with the prognosis in salivary gland cancer (SGC), indicating that they contribute to the progression and invasion of these malignant tumours. Objectives. Elevated levels of certain MMPs have been detected in various advanced human cancer types. The purpose of the study was to analyse the expression of MMP-1, -9 and -13 in SGC by immunohistochemistry and correlate the results to the clinical data and 10-year survival of SGC patients in a nationwide material. Materials and methods. Immunohistochemistry for MMP-1, -9 and -13 was performed in series of 103 paraffin-embedded sections of SGC. Results. High MMP-13 staining intensity predicted poor survival (3 vs 1; p=0.08) in the whole material studied. High MMP-13 intensity (2+3 vs 1; p=0.05), percentage (2 vs 1; p=0.03) and index (3 vs 1; p=0.02) were associated with poor survival in acinic cell carcinoma. However, high MMP-9 index in adenoid cystic carcinoma (p=0.06) and the percentage of positively staining cells in salivary duct carcinoma patients (p=0.05) was associated with poor survival. High MMP-1 staining intensity (2 vs 0; p=0.06) and index (% * intensity); (2 vs 1, p=0.04) were associated with better overall survival in the whole material.


Journal of Investigative Dermatology | 2015

Complement Factor I Promotes Progression of Cutaneous Squamous Cell Carcinoma

Pilvi Riihilä; Liisa Nissinen; Mehdi Farshchian; Atte Kivisaari; Risto Ala-aho; Markku Kallajoki; Reidar Grénman; Seppo Meri; Sirkku Peltonen; Juha Peltonen; Veli-Matti Kähäri

The incidence of cutaneous squamous cell carcinoma (cSCC) is rising worldwide. We have examined the role of complement components in the progression of cSCC. Analysis of cSCC cell lines (n=8) and normal human epidermal keratinocytes (n=11) with whole transcriptome profiling (SOLiD), quantitative real-time reverse transcriptase-PCR, and western blotting revealed marked overexpression of complement factor I (CFI) in cSCC cells. Immunohistochemical analysis for CFI in vivo showed stronger tumor cell-specific labeling intensity in invasive sporadic cSCCs (n=83) and recessive dystrophic epidermolysis bullosa-associated cSCCs (n=7) than in cSCC in situ (n=65), premalignant epidermal lesions (actinic keratoses, n=64), benign epidermal papillomas (seborrheic keratoses, n=39), and normal skin (n=9). The expression of CFI was higher in the aggressive Ha-ras-transformed cell line (RT3) than in less tumorigenic HaCaT cell lines (HaCaT, A5, and II-4). The expression of CFI by cSCC cells was upregulated by IFN-γ and IL-1β. Knockdown of CFI expression inhibited proliferation and migration of cSCC cells and resulted in inhibition of basal extracellular signal-regulated kinase (ERK) 1/2 activation. Knockdown of CFI expression potently inhibited growth of human cSCC xenograft tumors in vivo. These results provide evidence for the role of CFI in the progression of cSCC and identify it as a potential therapeutic target in this nonmelanoma skin cancer.


World journal of clinical oncology | 2013

Squamous cell carcinoma of the skin: Emerging need for novel biomarkers.

Atte Kivisaari; Veli-Matti Kähäri

The incidence of non-melanoma skin cancers (NMSC) is rising worldwide resulting in demand for clinically useful prognostic biomarkers for these malignant tumors, especially for invasive and metastatic cutaneous squamous cell carcinoma (cSCC). Important risk factors for the development and progression of cSCC include ultraviolet radiation, chronic skin ulcers and immunosuppression. Due to the role of cumulative long-term sun exposure, cSCC is usually a disease of the elderly, but the incidence is also growing in younger individuals due to increased recreational exposure to sunlight. Although clinical diagnosis of cSCC is usually easy and treatment with surgical excision curable, it is responsible for the majority of NMSC related deaths. Clinicians treating skin cancer patients are aware that certain cSCCs grow rapidly and metastasize, but the underlying molecular mechanisms responsible for the aggressive progression of a subpopulation of cSCCs remain incompletely understood. Recently, new molecular markers for progression of cSCC have been identified.


Acta Oncologica | 2010

Matrix metalloproteinase (MMP)-7 in salivary gland cancer.

Heikki Luukkaa; Pekka J. Klemi; Pirkko Hirsimäki; Tero Vahlberg; Atte Kivisaari; Veli-Matti Kähäri; Reidar Grénman

Introduction. High levels of certain matrix metalloproteinases (MMPs) have been detected in various human cancers. The purpose of this study was to analyze the expression of MMP-7 in salivary gland cancer (SGC) by immunohistochemistry and to associate the results with the clinical data and the 10-year survival of the SGC patients. Material and methods. Immunohistochemistry for MMP-7 was performed in a series of 107 paraffin-embedded sections of SGC. The samples represent the entire SGC population in Finland from 1991–1996. Mortality follow-up ended December 31, 2006. Results. The study population of 107 patients consisted of 47 male and 60 female subjects, ranging in age at the time of diagnosis between 23 and 90 years. The minimum follow-up time was 10.6 years and the maximum 15.9 years. By age-adjusted analysis lower staining intensity was associated with worse overall survival of patients with acinic cell carcinoma (p = 0.047, HR 6.5, 95% Cl 1.0–41.7) and in mucoepidermoid carcinoma (p = 0.010, HR 9.3, 95% CI 1.7–50.0). Low staining intensity was also associated with worse disease-specific survival of patients with acinic cell carcinoma (0–1 vs. 2–3; p = 0.047, HR 13.7, 1.0–200.0). VCI Ki-67 was an important prognostic factor for survival of the entire data set (p < 0.0001, HR 4.7, 95% Cl 2.3–9.8). Conclusions. MMP-7 is associated with the prognosis of patients with acinic cell and mucoepidermoid carcinoma.


Journal of the National Cancer Institute | 2016

Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC

V. Martins; M. Caley; Kate M. Moore; Z Szentpetery; S. Marsh; Dédée F. Murrell; Minhee Kim; M Avari; John A. McGrath; R. Cerio; Atte Kivisaari; Veli-Matti Kähäri; Kairbaan Hodivala-Dilke; Caroline H. Brennan; Mei Chen; John Marshall; Edel A. O'Toole

BACKGROUND Individuals with severe generalized recessive dystrophic epidermolysis bullosa (RDEB), an inherited blistering disorder caused by mutations in the COL7A1 gene, develop unexplained aggressive squamous cell carcinomas (SCC). Here we report that loss of type VII collagen (Col7) in SCC results in increased TGFβ signaling and angiogenesis in vitro and in vivo. METHODS Stable knockdown (KD) of Col7 was established using shRNA, and cells were used in a mouse xenograft model. Angiogenesis was assessed by immunohistochemistry, endothelial tube-forming assays, and proteome arrays. Mouse and zebrafish models were used to examine the effect of recombinant Col7 on angiogenesis. Findings were confirmed in anonymized, archival human tissue: RDEB SCC tumors, non-EB SCC tumors, RDEB skin, normal skin; and two human RDEB SCC cell lines. The TGFβ pathway was examined using immunoblotting, immunohistochemistry, biochemical inhibition, and siRNA. All statistical tests were two-sided. RESULTS Increased numbers of cross-cut blood vessels were observed in Col7 KD compared with control xenografts (n = 4 to 7 per group) and in RDEB tumors (n = 21) compared with sporadic SCC (n = 24, P < .001). Recombinant human Col7 reversed the increased SCC angiogenesis in Col7 KD xenografts in vivo (n = 7 per group, P = .04). Blocking the interaction between α2β1 integrin and Col7 increased TGFB1 mRNA expression 1.8-fold and p-Smad2 levels two-fold. Increased TGFβ signaling and VEGF expression were observed in Col7 KD xenografts (n = 4) compared with control (n = 4) and RDEB tumors (TGFβ markers, n = 6; VEGF, n = 17) compared with sporadic SCC (TGFβ markers, n = 6; VEGF, n = 21). Inhibition of TGFβ receptor signaling using siRNA resulted in decreased endothelial cell tube formation (n = 9 per group, mean tubes per well siC = 63.6, SD = 17.1; mean tubes per well siTβRII = 29.7, SD = 6.1, P = .02). CONCLUSIONS Type VII collagen suppresses TGFβ signaling and angiogenesis in cutaneous SCC. Patients with RDEB SCC may benefit from anti-angiogenic therapy.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2009

EXPRESSION OF MATRIX METALLOPROTEINASE-1, -7, -9, -13, Ki-67, AND HER-2 IN EPITHELIAL-MYOEPITHELIAL SALIVARY GLAND CANCER

Heikki Luukkaa; Pekka J. Klemi; Ilmo Leivo; Antti A. Mäkitie; Jonathan C. Irish; Ralph W. Gilbert; Bayardo Perez-Ordonez; Pirkko Hirsimäki; Tero Vahlberg; Atte Kivisaari; Veli-Matti Kähäri; Reidar Grénman

The expression of matrix metalloproteinases (MMPs) in epithelial‐myoepithelial salivary gland carcinoma has not been studied previously.


Journal of Investigative Dermatology | 2015

EphB2 Promotes Progression of Cutaneous Squamous Cell Carcinoma.

Mehdi Farshchian; Liisa Nissinen; Elina Siljamäki; Pilvi Riihilä; Mervi Toriseva; Atte Kivisaari; Risto Ala-aho; Markku Kallajoki; Esko Veräjänkorva; Hanne-Kaisa Honkanen; Ritva Heljasvaara; Taina Pihlajaniemi; Reidar Grénman; Juha Peltonen; Sirkku Peltonen; Veli-Matti Kähäri

Keratinocyte-derived skin cancer, cutaneous squamous cell carcinoma (cSCC), is the most common metastatic skin cancer. We have examined the role of Eph/ephrin signaling in the progression of cSCC. Analysis of the expression of EPH and EFN families in cSCC cells and normal epidermal keratinocytes revealed overexpression of EPHB2 mRNA in cSCC cells and cSCC tumors in vivo. Tumor cell-specific overexpression of EphB2 was detected in human cSCCs and in chemically induced mouse cSCCs with immunohistochemistry, whereas the expression of EphB2 was low in premalignant lesions and normal skin. Knockdown of EphB2 expression in cSCC cells suppressed growth and vascularization of cSCC xenografts in vivo and inhibited proliferation, migration, and invasion of cSCC cells in culture. EphB2 knockdown downregulated expression of genes associated with biofunctions cell viability, migration of tumor cells, and invasion of tumor cells. Among the genes most downregulated by EphB2 knockdown were MMP1 and MMP13. Moreover, activation of EphB2 signaling by ephrin-B2-Fc enhanced production of invasion proteinases matrix metalloproteinase-13 (MMP13) and MMP1, and invasion of cSCC cells. These findings provide mechanistic evidence for the role of EphB2 in the early progression of cSCC to the invasive stage and identify EphB2 as a putative therapeutic target in this invasive skin cancer.

Collaboration


Dive into the Atte Kivisaari's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Reidar Grénman

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pilvi Riihilä

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar

Sirkku Peltonen

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Seppo Meri

University of Helsinki

View shared research outputs
Researchain Logo
Decentralizing Knowledge